| 10.38 0 (0%) | 01-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.14 | 1-year : | 14.18 |
| Resists | First : | 10.39 | Second : | 12.14 |
| Pivot price | 10.37  |
|||
| Supports | First : | 10.35 | Second : | 10.32 |
| MAs | MA(5) : | 10.37 | MA(20) : | 10.36 |
| MA(100) : | 10.31 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 56.7 |
D(3) : | 54.8 |
| RSI | RSI(14): 66.9 | |||
| 52-week | High : | 10.39 | Low : | 9.96 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ DMAA ] has closed below upper band by 17.8%. Bollinger Bands are 36.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.39 - 10.44 | 10.44 - 10.48 |
| Low: | 10.24 - 10.3 | 10.3 - 10.35 |
| Close: | 10.29 - 10.38 | 10.38 - 10.46 |
Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.
Thu, 02 Oct 2025
Drugs Made In America Acquisition II Corp. completes $500 million IPO and private placement - Investing.com
Thu, 25 Sep 2025
Drugs Made In America Acquisition II prices $500 million IPO at $10 per unit - Investing.com
Tue, 18 Feb 2025
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView — Track All Markets
Wed, 29 Jan 2025
Drugs Made In America Acquisition Corp. Completes $200 Million IPO on Nasdaq - Nasdaq
Mon, 27 Jan 2025
Drugs Made In America Acquisition Corp. Sets Pricing for Initial Public Offering of 20 Million Units at $10 Each - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Shell Companies
|
|
| Shares Out | 34 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 26.7 (%) |
| Held by Institutions | 66.3 (%) |
| Shares Short | 42 (K) |
| Shares Short P.Month | 54 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.22 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | -47.19 |
| Price to Sales | 0 |
| Price to Cash Flow | -647.74 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|